Silibinin, a natural flavonoid,modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 849-854

  Kauntz, Henriette ^a   Bousserouel, Souad ^a   Gosse, Francine ^a   Marescaux, Jacques ^b   Raul, Francis ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b IRCAD   (France)

Author keywords

Aberrant crypt foci; Apoptosis; Colorectal cancer; Inflammation

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; FLAVONOID; INTERLEUKIN 1BETA; MATRILYSIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; SILIBININ; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL RENEWAL; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; CRYPT CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SILYBUM MARIANUM; TREATMENT DURATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; APOPTOSIS; AZOXYMETHANE; CASPASE 3; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; DOWN-REGULATION; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MALE; MATRIX METALLOPROTEINASE 7; MILK THISTLE; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-BCL-2; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; SILYMARIN; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84864992319     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1526     Document Type: Article

References (37)

1. Boursi B and Arber N: Current and future clinical strategies in colon cancer prevention and the emerging role of chemoprevention. Curr Pharm Des 13: 2274-2282, 2007. (Pubitemid 47317035)
2. Reddy BS: Studies with azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 44: 26-35, 2004.
3. Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon cancer chemoprevention in rats, mice and humans. Eur J Cancer 41: 1911-1922, 2005. (Pubitemid 41557677)
4. Hoensch HP and Kirch W: Potential role of flavonoids in the prevention of intestinal neoplasia: a review of their mode of action and their clinical perspectives. Int J Gastrointest Cancer 35: 187-195, 2005.
5. Terpstra OT, Van Blankenstein M, Dees J and Eilers GA: Abnormal pattern of cell proliferation in the entire colonic mucosa of patients with colon adenoma or cancer. Gastroenterology 92: 704-708, 1987. (Pubitemid 17023734)
6. Risio M, Lipkin M, Candelaresi G, Bertone A, Coverlizza S and Rossini FP: Correlations between rectal mucosa cell proliferation and the clinical and pathological features of nonfamilial neoplasia of the large intestine. Cancer Res 151: 1917-1921, 1999.
7. Pereira MA, Barnes LH, Rassman VL, Kelloff GV and Steele VE: Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15: 1049-1054, 1994. (Pubitemid 24156909)
8. Bird RP and Good K: The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 112-113: 395-402, 2000. (Pubitemid 30138150)
9. Gazàk R, Walterovà D and Kren V: Silybin and silymarin - new and emerging applications in medicine. Curr Med Chem 14: 315-338, 2007.
10. Singh RP and Agarwal R: Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer 41: 1969-1979, 2005. (Pubitemid 41557682)
11. Singh RP and Agarwal R: Prostate cancer chemoprevention by silibinin: bench to bedside. Mol Carcinog 45: 436-442, 2006. (Pubitemid 43865852)
12. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, Radcliffe RA, Malkinson AM and Agarwal R: Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res (Phila) 2: 74-83, 2009.
13. Velmurugan B, Singh RP, Tyagi A and Agarwal R: Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher rats. Cancer Prev Res (Phila) 1: 376-385, 2008.
14. Kaur M, Velmurugan B, Tyagi A, Agarwal C, Singh RP and Agarwal R: Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through downregulation of beta-catenin-dependent signaling. Neoplasia 12: 415-424, 2010.
15. Ravichandran K, Velmurugan B, Gu M, Singh RP and Agarwal R: Inhibitory effect of silibinin against azoxymethane-induced colon tumorigenesis in A/J mice. Clin Cancer Res 16: 4595-4606, 2010.
16. Kauntz H, Bousserouel S, Gossé F and Raul F: Silibinin triggers apoptotic signaling pathways and autophagic survival response in human colon adenocarcinoma cells and their derived meta-static cells. Apoptosis 16: 1042-1053, 2011.
17. Bousserouel S, Kauntz H, Gossé F, Bouhadjar M, Soler L, Marescaux J and Raul F: Identification of gene expression profiles correlated to tumor progression in a preclinical model of colon carcinogenesis. Int J Oncol 36: 1485-1490, 2010.
18. Charnley G and Tannenbaum SR: Flow cytometric analysis of the effect of sodium chloride on gastric cancer risk in the rat. Cancer Res 45: 5608-5616, 1985. (Pubitemid 16218562)
19. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001. (Pubitemid 34164012)
20. Sier CF, Hawinkels LJ, Zijlmans HJ, Zuidwijk K, de Jonge-Muller ES, Ferreira V, Hanemaaijer R, Mulder-Stapel AA, Kenter GG, Verspaget HW and Gorter A: Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biol 27: 267-271, 2008. (Pubitemid 351384767)
21. Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 20: 983-1002, 2006. (Pubitemid 44356460)
22. Gunter MJ: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15: 1126-1131, 2006.
23. Buck I, Morceau F, Grigorakaki C, Dicato M and Diederich M: Linking anemia to inflammation and cancer: the crucial role of TNFα. Biochem Pharmacol 77: 1572-1579, 2009.
24. Riccardi C and Nicoletti I: Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458-1461, 2006.
25. Corpet DE and Tache S: Most effective colon cancer chemopreventive agents in rats: a review of aberrant crypt foci and tumour data, ranked by potency. Nutr Cancer 43: 1-21, 2002. (Pubitemid 35387251)
26. Pereira MA, Barnes LH, Rassman VL, Kelloff GV and Steele VE: Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents. Carcinogenesis 15: 1049-1054, 1994. (Pubitemid 24156909)
27. Pretlow TP, O'Riordan MA, Pretlow TG and Stellato TA: Aberrant crypts in human colonic mucosa: Putative preneoplastic lesions. J Cell Biochem (Suppl) 16: G55-G62, 1992.
28. Takayama T, Katsuki S, Takahashi Y, et al: Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339: 1277-1284, 1998. (Pubitemid 28496193)
29. Leeman MF, Curran S and Murray GI: New insights into the roles of matrix metalloproteinases in colorectal cancer development and progression. J Pathol 201: 528-534, 2003. (Pubitemid 38256401)
30. Lu Q, Jiang B, Lin C and Shan T: Dark aberrant crypt foci with activated Wnt pathway are related to tumorigenesis in the colon of AOM-treated rat. J Exp Clin Cancer Res 27: 26, 2008.
31. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, Betz KS, Penz-Oesterreicher M, Bjorkdahl O, Fox JG and Wang TC: Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 14: 408-419, 2008.
32. Anti M, Armuzzia A, Morinid S, Iasconea E, Pignataroa G, Cocob C, Lorenzettie R, Paoluccia M, Covinoa M, Gasbarrinia A, et al: Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas. Gut 48: 238-246, 2001. (Pubitemid 32141850)
33. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
34. Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell 144: 646-674, 2011.
35. Singh RP, Tyagi AK, Zhao J and Agarwal R: Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis 23: 499-510, 2002. (Pubitemid 34257631)
36. Bousserouel S, Gossé F, Bouhadjar M, Soler L, Marescaux J and Raul F: Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep 23: 511-517, 2010.
37. Bousserouel S, Lamy V, Gossé F, Lobstein A, Marescaux J and Raul F: Early modulation of gene expression used as biomarker for chemoprevention in a preclinical model of colon carcinogenesis. Path Int 61: 80-87, 2011.